Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. - sprookjes - yvandenbroek - TriplyDB

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

http://www.wikidata.org/entity/Q34636874

about

Inducing and Administering Tregs to Treat Human Disease Type-2 innate lymphoid cells control the development of atherosclerosis in mice Therapeutic window of interleukin-2 for autoimmune diseases.T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production.Targeting Treg signaling for the treatment of autoimmune diseases Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5.Regulation of metabolic health and adipose tissue function by group 2 innate lymphoid cells Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection.The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.Group 2 innate lymphoid cells in disease.CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.Immune-mediated mechanisms of atherosclerosis and implications for the clinic.Innate lymphoid cell function in the context of adaptive immunity Restoring Regulatory T Cells in Type 1 Diabetes.Group 2 ILCs: A way of enhancing immune protection against human helminths?Innate lymphoid cells at the interface between obesity and asthma.T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow.Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.Group 2 Innate Lymphoid Cells Are Involved in Skewed Type 2 Immunity of Gastric Diseases Induced by Helicobacter pylori Infection.Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation.Group 2 Innate Lymphoid Cells Exhibit a Dynamic Phenotype in Allergic Airway Inflammation.Alternative activation generates IL-10 producing type 2 innate lymphoid cells.Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity.Adipose-tissue regulatory T cells: Critical players in adipose-immune crosstalk.Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.T cells are necessary for ILC2 activation in house dust mite-induced allergic airway inflammation in mice.

P2860

Q26772723-BD6E5E25-1FDC-4B38-BB8E-3F5A9BDC26B4 Q33786641-EDCEF50E-9213-4D25-B9B7-4EB8DB1CE67B Q35630817-769FC02B-9245-4FE2-8796-4A4BDDC45A28 Q35940715-790605B4-10EC-4ACC-9850-9ABAAB8427AF Q36372616-4FC7F8D7-7605-4CEC-AE13-221FE70B78BB Q37076418-28A3075B-7022-4EAC-B723-99A3C4802ABB Q37158737-C6D835D9-3C30-41AD-9F46-067FF8540DB5 Q37313634-28DD120C-DE6B-4E9B-AE6A-88ADB309D00C Q37563901-C223DFFB-E152-43B6-BF13-FC2BD7A313F2 Q37600819-DD70519E-5024-4763-8D17-780BE6B5767D Q38424758-E2850944-6330-433D-82BB-B03E49A34BBE Q38573631-4A9B7CEA-0A6E-4DAB-8002-5F9CE9A5C6A1 Q38577294-7FC43469-F9C8-4116-BC71-36DA8353EE0D Q38736845-11998705-3EB7-4AD6-8E5C-7E8913D465DC Q38851472-CBB29D95-BD4B-4668-9708-1F0E6550A085 Q38872152-3D11F106-F76B-42D1-9813-80197F0A6581 Q38963375-4360AEE3-2383-4CE1-B31A-E61B181553AF Q39381981-B207EB0A-2292-4326-806B-78D8BF193F46 Q40062668-3700233E-AF01-4A90-AC63-FEE3B01DF578 Q40321710-617B34A0-D8B7-4A90-8043-2A489AF52054 Q41149769-41CE0648-14D9-42FF-A48A-56ED29EA0BCB Q43375960-D1AF803C-26A3-4D19-A9F0-073888CEB10D Q46268804-9F403FEA-9FA6-49C5-8BB4-C467B0F0704F Q47095720-241229FE-50A9-41DB-AA39-E5B24E607942 Q47132488-2AD97E5A-F5C0-4419-AA13-D90A0EECF7C9 Q47913432-E0347D83-9A36-4870-B4AB-7D88DC2BF0F6 Q48164917-5020DFC3-F76F-42BD-97D5-42A745B5BE98 Q50030501-E1B3056B-A36B-416C-A27E-AB617C135680 Q53125837-99179FFB-DA3B-45B5-AD19-9F01D14E882B

P2860

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

http://www.wikidata.org/entity/Q34636874

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@ast

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@en

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@nl

type

label

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@ast

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@en

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@nl

prefLabel

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@ast

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@en

Interleukin-5-producing group ...... uced by interleukin-2 therapy.

@nl

P1433

Q34636874-BD77A1C6-952B-4023-A949-A06152C3B83D

P1476

Q34636874-3537F65B-C2F0-4053-9A8E-0241203C3D26

P2093

Q34636874-00E2A652-F27E-450D-96C0-C0ABF5665B0F

Q34636874-0690A712-A376-41A9-936A-8CF7D460D311

Q34636874-48801FAD-6CB5-4C71-A6CC-F3535514B1E5

Q34636874-80921CDA-6A47-43DB-92D7-3D2E54D6F93E

Q34636874-B67916F5-FB94-415F-AB51-6B785936F2CA

P2860

Q34636874-0DBB60D8-9CF1-4348-AB50-DD86D42EDEB8

Q34636874-15CFAC7A-2824-4325-8231-64038E2E5753

Q34636874-16D1EDB2-C554-4697-ADD7-BF2802961952

Q34636874-256C0508-00D0-4F28-B497-40597445A71C

Q34636874-52BD8F5A-0E82-45B4-A471-5F10238C6C22

Q34636874-56ADB03E-E944-4CF6-9149-0B4F425E5C27

Q34636874-63D9605F-BCAD-425A-932B-72218D8E81E0

Q34636874-68C601FC-DD68-472C-B490-51AA85EA02B3

Q34636874-6D8433AE-2110-421A-8671-163E644AEE82

Q34636874-6EE892E4-B1BB-4591-ADA8-6A15D8C51C84

P304

Q34636874-9639F97B-63E5-44AD-824A-211D1432CDA4

P31

Q34636874-80DDF6FF-B0D6-4B3D-8525-605958FC6A84

P356

Q34636874-EDCF2A02-CFEB-4466-ACD3-8570ABDC400F

P407

Q34636874-215886D8-A8AC-42F1-AEB4-664CFC9C82B5

P433

Q34636874-37CE5035-A913-417F-99CE-C8E5FCB325C8

P478

Q34636874-FF7B3C88-FCF3-48C5-B8C2-4BAD331876F5

P50

Q34636874-8CC8A6C5-88E0-4ABF-94D6-3CEAD177D594

Q34636874-B641B2AE-AA1D-4113-A704-E4D87C50F36E

Q34636874-FFD28194-E468-4EF9-B06A-2C7857DA1535

P577

Q34636874-5486AE36-D9A9-42BE-9E83-2C5653A36A49

P5875

Q34636874-1263782E-A927-4C39-BC3A-5640F42E0FC5

P698

Q34636874-9BF50E11-2E43-4C96-9DCB-B1C7EB739278

P921

Q34636874-622bd901-7434-40d5-b93d-60ac12fc92e2

P932

Q34636874-1358D707-BD74-4EAB-BFDB-8111A9062C50

P356

BLOOD-2014-07-587493

P1433

P1476

Interleukin-5-producing group ...... duced by interleukin-2 therapy

@en

P2093

Frédéric Van Gool

http://www.w3.org/2001/XMLSchema#string

Hong-Erh Liang

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Bluestone

http://www.w3.org/2001/XMLSchema#string

Malika M Morar

http://www.w3.org/2001/XMLSchema#string

Richard M Locksley

http://www.w3.org/2001/XMLSchema#string

P2860

Systemically dispersed innate IL-13-expressing cells in type 2 immunity

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells

Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.

The role of interleukin-2 during homeostasis and activation of the immune system.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy

P304

3572-3576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-07-587493

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

David Klatzmann

Michelle Rosenzwajg

P577

2014-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267043970

http://www.w3.org/2001/XMLSchema#string

P698

25323825

http://www.w3.org/2001/XMLSchema#string

P921

P932

4256909

http://www.w3.org/2001/XMLSchema#string